Literature DB >> 8398577

Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.

K Brøsen1, E Skjelbo, H Flachs.   

Abstract

1. A sparteine/mephenytoin phenotyping test was carried out in 37 Vietnamese living in Denmark. By visual inspection the urinary S/R-mephenytoin ratio appeared to show a bimodal frequency distribution. Eight putative poor metabolizers of mephenytoin, PMm (22%), had S/R-mephenytoin ratios from 0.79 to 1.12 and 29 putative extensive metabolizers of mephenytoin, EMm, had S/R-mephenytoin ratios < or = 0.55. All of the subjects were extensive metabolizers of sparteine with urinary metabolic ratios from 0.15 to 2.4. 2. The metabolism of the antimalarial prodrug proguanil was studied in 34 of the subjects after a single oral dose of 100 mg. The median 12 h urinary recoveries of the active metabolite cycloguanil and the minor metabolite 4-chlorphenylbiguanide were 5.8 and 1.9% of the dose, respectively, in 26 EMm compared with 1.6 and 0.4%, respectively, in 8 PMm (P < 0.001, Mann-Whitney U-test). 3. There was no statistically significant correlation (Spearmans rs) between any index of proguanil metabolism and the sparteine metabolic ratio.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398577      PMCID: PMC1364572          DOI: 10.1111/j.1365-2125.1993.tb04204.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping southeastern Oriental subjects.

Authors:  R Setiabudy; K Chiba; M Kusaka; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

2.  Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.

Authors:  L Bertilsson; Y Q Lou; Y L Du; Y Liu; T Y Kuang; X M Liao; K Y Wang; J Reviriego; L Iselius; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1992-04       Impact factor: 6.875

3.  Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans.

Authors:  C Funck-Brentano; O Bosco; E Jacqz-Aigrain; A Keundjian; P Jaillon
Journal:  Clin Pharmacol Ther       Date:  1992-05       Impact factor: 6.875

4.  Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies.

Authors:  Y Zhang; R A Blouin; P J McNamara; J Steinmetz; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

5.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

6.  Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland.

Authors:  K Clasen; L Madsen; K Brøsen; K Albøge; S Misfeldt; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1991-06       Impact factor: 6.875

7.  Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA.

Authors:  H Furuya; U A Meyer; H V Gelboin; F J Gonzalez
Journal:  Mol Pharmacol       Date:  1991-09       Impact factor: 4.436

8.  The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.

Authors:  S A Ward; N A Helsby; E Skjelbo; K Brøsen; L F Gram; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

9.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

10.  Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.

Authors:  D R Sohn; M Kusaka; T Ishizaki; S G Shin; I J Jang; J G Shin; K Chiba
Journal:  Clin Pharmacol Ther       Date:  1992-08       Impact factor: 6.875

View more
  7 in total

1.  CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.

Authors:  S Kortunay; A Bozkurt; L Bathum; N E Basci; M Calgüneri; K Brøsen; S O Kayaalp
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

Review 2.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 3.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.

Authors:  J M Hoskins; G M Shenfield; A S Gross
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

5.  Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.

Authors:  Janelle M Hoskins; Gillian M Shenfield; Annette S Gross
Journal:  Eur J Clin Pharmacol       Date:  2003-09-12       Impact factor: 2.953

6.  Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population.

Authors:  R Setiabudy; M Kusaka; K Chiba; I Darmansjah; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

7.  Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle-cell disease patients and healthy controls in Nigeria.

Authors:  Olufunmilayo E Adejumo; Taiwo R Kotila; Adeyinka G Falusi; Boladale O Silva; Jacinta N Nwogu; Pius S Fasinu; Chinedum P Babalola
Journal:  Pharmacol Res Perspect       Date:  2016-08-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.